Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib | Zendy

Sebastian Szmit | Zendy; Magdalena Zaborowska | Zendy; Anna Waśko-Grabowska | Zendy; Jakub Żołnierek | Zendy; Paweł Nurzyński | Zendy; Krzysztof J. Filipiak‬ | Zendy; Grzegorz Opolski | Zendy; Cezary Szczylik | Zendy

Open Access

Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib

Author(s) -

Sebastian Szmit,

Magdalena Zaborowska,

Anna Waśko-Grabowska,

Jakub Żołnierek,

Paweł Nurzyński,

Krzysztof J. Filipiak‬,

Grzegorz Opolski,

Cezary Szczylik

Publication year - 2012

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000338175

Subject(s) - sorafenib , medicine , renal cell carcinoma , blood pressure , cardiology , coronary artery disease , gastroenterology , urology , hepatocellular carcinoma , oncology

The purpose of the present study was to determine the relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research